Trial Profile
Fotemustine + bevacizumab as second-line treatment in glioma: a phase II study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fotemustine (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 18 Aug 2015 New trial record
- 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.